MoleMap Australia & New Zealand’s Post

With the IND approval from the FDA, we dosed our first patient in the US today in our Phase I/IIa study, NAPISTAR 1-01. Entering the clinic with our first candidate from our growing pipeline of next-generation #ADCs marks an important milestone for Tubulis and we look forward to bringing the true value of ADCs to patients with solid tumors.   The first-in-human trial is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TUB-040, one of our lead candidates, as a monotherapy in patients with platinum-resistant, high-grade #OvarianCancer (PROC) or relapsed/refractory adenocarcinoma non-small cell lung cancer (#NSCLC), who have exhausted all other available treatment options. TUB-040 is a topoisomerase-I-based ADC targeting NaPi2b, which showed superior biophysical properties in preclinical studies indicating a high potential to improve efficient long-term anti-tumor responses.   Find the full press release here: https://bit.ly/3Xydc3K. If you want to read more on our proprietary suite of platform technologies and vision to usher in a new ADC era for better patient outcomes at www.tubulis.com

The importance of routine screening and early detection is key.

Interesting discussion at The Cancer Drug Development Forum (CDDF) workshop regarding access to molecular diagnostics and the waste of healthcare resources and patients' lives by not implementing the right biomarkers. For instance, not identifying oncogene-addicted #NSCLC tumours (both in metastatic and early settings) and instead treating all patients with immune-checkpoint inhibitors, or not screening for #RAS G12 in metastatic colorectal cancer before prescribing trifluridine/tipiracil, or not following the workup for cancer of unknown primary (#CUP)…. Increased transparency regarding testing can highlight challenges at the national level and provide solutions. Thanks to Jaap Verweij, Warnyta Minnaard, Peter Keeling, Ademi Santiago-Walker, Rosa Giuliani, Hyunmin Park & Caroline Marissal / Missie Tumor Onbekend

Gastrointestinal Research Coordinators at UVACCC’s Office of Clinical Research (OCR) help patients participate in therapeutic clinical trials and researchers as they evaluate new treatments. A unique trial for patients with bile duct cancer is currently underway, testing the use of a new drug. Paul Kunk, MD, the trial’s Principal Investigator, is optimistic about the possibilities this trial offers for participants. Bile duct cancer is complex and patients with advanced bile duct cancer with specific protein mutations, such as FGFR2, have limited options after progression on targeted therapy. Most of these patients undergo cytotoxic chemotherapy, but this trial provides a much better option of additional oral targeted therapy. OCR’s GI team brings new hope to patients through their work on clinical trials. To learn more about this clinical trial or others, click here: https://bit.ly/4bF0OSG #UVA #CancerResearch #ClinicalTrials #GastrointestinalCancer #GastrointestinalCancerAwareness

No longer defined by a paucity of effective treatments, bladder cancer has moved into the era of precision medicine. With immune checkpoint inhibitors, fibroblast growth factor receptor (#FGFR) inhibitors, and antibody–drug conjugates (#ADCs) approved or being studied as monotherapy or in combination with other agents, these treatment innovations, along with novel approaches to drug delivery, have brought new hope for patients with advanced or metastatic disease and are increasingly providing options in earlier stages of disease, including high-risk non–muscle-invasive bladder cancer (#NMIBC) and muscle-invasive bladder cancer (#MIBC). Register now to attend a new event from PVI, PeerView Institute for Medical Education Live, and Bladder Cancer Advocacy Network that features guidance from a panel of experts led by chair Andrea Necchi, MD, on bringing state-of-the-art care to patients in a variety of settings. Join the experts in person at #ASCO24 or online on May 31 at 6:30 PM CDT! https://lnkd.in/e59Bmk3S #MedEd #Oncology #Urology This activity is supported through educational grants from from Astellas Pharma and Pfizer, Bristol Myers Squibb, The Janssen Pharmaceutical Companies of Johnson & Johnson, and Merck.

How can we address the unmet need for "clean" targets for ADCs?   Current antibody-based therapies can only be used effectively in specific cancer types due to a lack of truly cancer-specific therapeutic targets. The antigens targeted by these treatments are often present on both cancerous and healthy cells, meaning most ADCs exhibit on-target / off-tissue toxicities.    At BiVictriX, our unique Bi-Cygni® bispecific platform targets twin antigen pairs present only on cancer cells, meaning we are able to increase the maximum tolerated dose of our ADCs, widen the therapeutic window, and ultimately improve patient outcomes. There are a lot of exciting developments happening here at BiVictriX, and we can’t wait to share them with you. Head to our website to learn more about our science: https://lnkd.in/eBHU7BJH or reach out to one of our team: https://lnkd.in/ePPmnr_Q    #ADC #drugdevelopment #antibodytherapeutics #immunotherapy #Biotech #oncology #therapeutics #bispecific

✨ ACCENT Trial Update    #Amplia has today released an update on the ACCENT trial in pancreatic cancer.    Following the completion of the Phase 1b portion of the trial in November, a safe and well-tolerated dose of 400 mg narmafotinib once-a-day was identified. Response rates from the Phase 1b portion of the trial continue to be substantially better in terms of clinical response and duration on trial, when compared to treatment with chemotherapy alone. Recruitment for the Phase 2a stage of the trial is progressing well, with 11 patients currently enrolled in the Phase 2a cohort –  7 patients across Australian trial sites, and a further 4 pancreatic cancer patients in Korea.    The Phase 2a trial will initially enrol 26 patients and an interim analysis of efficacy will be conducted around Q3 2024.      Amplia CEO and MD, Dr Chris Burns, commented:     “The clinical responses we are seeing in patients is very promising and the duration on trial, given the aggressiveness of the disease in these patients, is also extremely encouraging.”    Read today’s ASX release 👉 https://lnkd.in/g78tsQyy     $ATX #ATX #ASX #pharma #biotech #innovation #cancertherapy #pancreaticcancer #clinicaltrial  

At Propanc Biopharma, we're committed to addressing the growing global need for innovative cancer treatments, particularly in the battle against solid tumor recurrence and metastasis. With an aging population and rising cancer rates projected by the World Health Organization, our focus is on developing our lead product, PRP. This therapy, based on a pancreatic proenzyme formulation, is designed to prevent tumor recurrence and metastasis, the leading causes of cancer-related deaths. PRP's unique approach aims to offer a significant advancement over current treatments, providing a new hope in the fight against pancreatic, ovarian, and colorectal cancers.    As we progress in our research and clinical trials, we remain dedicated to delivering breakthrough solutions to improve patient outcomes in oncology.   www.propanc.com #CancerResearch #Innovation #PropancBiopharma #PPCB Propanc Biopharma, Inc. (OTCQB:PPCB)

I will be in SF this Thursday and Friday at ASCO GI! Please let me know if you are attending and would like to connect to discuss our latest data in genomic profiling and MRD. #ASCOGI #predicine #MRD #precisionmedicine #liquidbiopsy

📊 Amador Study Share 📊 Excited to share an Amador-involved study presented at ASCPT 2024. The poster focuses on #PopPK modeling of Camrelizumab in patients with various cancers, including advanced hepatocellular carcinoma. Through modeling PK data from 10 clinical studies, including the Phase III pivotal trial, the PK model showed that: 🔹 Exposure was generally proportional to dose over a 200-600 mg dose range. 🔹 Median time to >90% of steady-state exposure (AUC) was estimated as ~16 weeks following the start of camrelizumab 200 mg Q2W dosing. 🔹 The model estimated 2.3-fold accumulation from the first dose to steady-state. 🔹 An effective half-life based on the model-predicted accumulation ratio was estimated as ~17 days. 🔔 Learn more, please click https://lnkd.in/gZgfXnxw #Pharmacokinetics #Camrelizumab #ASCPT2024 #DrugDevelopment #AmadorBio #Innovation